Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Finished Goods: 2020-2025

Historic Finished Goods for Maravai Lifesciences Holdings (MRVI) over the last 5 years, with Sep 2025 value amounting to $19.6 million.

  • Maravai Lifesciences Holdings' Finished Goods fell 14.79% to $19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.6 million, marking a year-over-year decrease of 14.79%. This contributed to the annual value of $23.1 million for FY2024, which is 18.98% up from last year.
  • According to the latest figures from Q3 2025, Maravai Lifesciences Holdings' Finished Goods is $19.6 million, which was down 0.62% from $19.7 million recorded in Q2 2025.
  • Maravai Lifesciences Holdings' 5-year Finished Goods high stood at $23.1 million for Q4 2024, and its period low was $6.3 million during Q2 2021.
  • In the last 3 years, Maravai Lifesciences Holdings' Finished Goods had a median value of $19.7 million in 2025 and averaged $18.2 million.
  • In the last 5 years, Maravai Lifesciences Holdings' Finished Goods declined by 26.16% in 2022 and then skyrocketed by 185.77% in 2024.
  • Maravai Lifesciences Holdings' Finished Goods (Quarterly) stood at $10.4 million in 2021, then decreased by 26.16% to $7.7 million in 2022, then surged by 151.15% to $19.4 million in 2023, then rose by 18.98% to $23.1 million in 2024, then fell by 14.79% to $19.6 million in 2025.
  • Its last three reported values are $19.6 million in Q3 2025, $19.7 million for Q2 2025, and $22.7 million during Q1 2025.